About Genor

Genor Biopharma Co. Ltd. was founded in December 2007. It is an innovation-driven international biopharmaceutical company, focusing on development and commercialization of therapeutic monoclonal antibodies (mAbs), Fc-fusion proteins and recombinant therapeutic proteins. Currently Genor has more than 10 products in pipeline, several of which have entered clinical stage. In December 2013, Genor was acquired by Walvax Biotechnology Co., Ltd (Walvax: 300142), a public listed biopharma in China.

Currently, Genor has more than 170 employees, most of which is R&D people. Genor have built a fully integrated R&D team led by a highly experienced Core Management Team. Each of the Core Management Team member has more than 15~20 years of industry experiences, and many of them came back from major western biopharmaceutical giants such as Amgen.

Genor has built end-to-end capabilities in research, development, production of therapeutic mAbs with mature technology platforms. Genor now has more than 6000 square meters of facility space, including R&D Labs, Process Development Labs, Analytical & Quality Center, and a cGMP Clinical Production Facility. A commercial scale cGMP production facility is also under design and construction.

Genor has a robust R&D mAbs pipeline, including blockbuster biosimilars and novel antibodies targeting unmet medical needs. Quite a few products take leading positions in China, and have been elected by central government for support of "National Key Drug R&D Program".

Collaboration is also a cornerstone of Genor's business strategy. In addition to in-house R&D, we are also actively seeking for partnership opportunities to enrich our pipeline, and to accelerate product development and commercialization.